Promega has entered a non-exclusive license agreement with the Broad Institute of MIT and Harvard to sell tools and reagents for CRISPR-Cas9 gene editing, the company announced today.

“With this combination of CRISPR and our most advanced reporter technologies like HiBiT, we are able to look at the dynamics of endogenous proteins in real time with unprecedented ease and sensitivity,” Promega Senior Research Scientist Thomas Machleidt said in a statement.

According to a release, Promega will combine CRISPR-Cas9 technology with its products that knock-in Promega genetic reporters to the genomes of any cell or cell line, enabling customers to explore endogenous biology at physiologically relevant expression levels.

Terms of the agreement were not disclosed.